International Journal of Hematology

, Volume 98, Issue 3, pp 323–330

Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study

  • Shinya Katsutani
  • Yoshiaki Tomiyama
  • Akiro Kimura
  • Yoshitaka Miyakawa
  • Shinichiro Okamoto
  • Yasushi Okoshi
  • Haruhiko Ninomiya
  • Hiroshi Kosugi
  • Kazuyoshi Ishii
  • Yasuo Ikeda
  • Toshihiro Hattori
  • Koichi Katsura
  • Yuzuru Kanakura
Original Article

Abstract

Eltrombopag is an oral, nonpeptide, thrombopoietin receptor agonist approved for treatment of chronic immune thrombocytopenia (ITP). The safety, tolerability, and efficacy of eltrombopag for up to 3 years were evaluated in 19 Japanese patients with chronic ITP who had completed a prior 6-month study. Patients received eltrombopag once daily at the last dosage received in the prior study (12.5, 25, or 50 mg). Dose adjustments and treatment interruptions were permitted to maintain platelet counts of 50,000–200,000/μL. Primary evaluations were safety and tolerability of long-term eltrombopag treatment. The median duration of exposure was 27.5 months (range, 9.9–32.3). Adverse events were similar to those reported with short-term use of eltrombopag, and none led to treatment discontinuation. Nine serious adverse events were reported. Median platelet counts began to increase after 1 week of treatment and remained above 50,000/μL for most assessments. Bleeding episodes decreased from 63 % at baseline to 21 % after 2 weeks of treatment and remained below baseline for all assessments. Of 15 patients receiving concomitant baseline ITP medications, 10 permanently discontinued or achieved a sustained reduction of at least one treatment without requiring rescue treatment. Long-term treatment with eltrombopag was safe, well tolerated, and effective in Japanese patients with chronic ITP.

Keywords

Bleeding Platelets Thrombopoietin receptor agonist 

References

  1. 1.
    Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.PubMedCrossRefGoogle Scholar
  2. 2.
    Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.PubMedCrossRefGoogle Scholar
  3. 3.
    Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93:329–35.PubMedCrossRefGoogle Scholar
  4. 4.
    Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol. 2003;25:660–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160:1630–8.PubMedCrossRefGoogle Scholar
  6. 6.
    McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104:956–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99:4–13.PubMedGoogle Scholar
  8. 8.
    Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005;90:72–7.PubMedGoogle Scholar
  9. 9.
    Fujimura K, Miyakawa Y, Kurata Y, Kuwana M, Tomiyama Y, Murata M. Reference guide for management of adult idiopathic thrombocytopenic purpura (ITP) 2012 version [Japanese]. Rinsho Ketsueki. 2012;53:433–42.PubMedGoogle Scholar
  10. 10.
    Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs. 2009;69:567–76.PubMedCrossRefGoogle Scholar
  11. 11.
    Promacta® (eltrombopag) prescribing information. Research Triangle Park, NC: GlaxoSmithKline, November 2012. http://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=1353688574915&featureKey=603802&tab=tab1&footer=yes&pTab=one#nlmhighlights. Accessed February 28, 2013.
  12. 12.
    Revolade® (eltrombopag). Summary of product characteristics. Cork, Ireland: GlaxoSmithKline, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001110/WC500089964.pdf. Accessed February 28, 2013.
  13. 13.
    Shida Y, Takahashi N, Nohda S, Hirama T. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Jpn J Clin Pharmacol Ther. 2011;42:11–20.CrossRefGoogle Scholar
  14. 14.
    Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51:842–56.PubMedCrossRefGoogle Scholar
  15. 15.
    Tomiyama Y, Miyakawa Y, Okamato S, Katsutani S, Kimura A, Okoshi Y, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2012;10:799–806.PubMedCrossRefGoogle Scholar
  16. 16.
    Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.PubMedGoogle Scholar
  17. 17.
    Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–47.PubMedCrossRefGoogle Scholar
  18. 18.
    Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377:393–402.PubMedCrossRefGoogle Scholar
  20. 20.
    Saleh MN, Cheng G, Bussel JB, Burgess P, Marcello L, Bailey CK, Brainsky A. Safety and efficacy of extended treatment with eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2011. Blood; 2011. p. 118: Abstract 3296.Google Scholar
  21. 21.
    Mufti G, Bagg A, Hasserjian R, Bain B, Kuter D, Dreiling L, Nichol J. Bone marrow reticulin in patients with immune thrombocytopenic purpura. Blood; 2006. p. 108: Abstract 3982.Google Scholar
  22. 22.
    Brynes RK, Orazi A, Verma S, Brainsky A, Bailey CK, Bakshi K. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with eltrombopag–data from the EXTEND study. Blood; 2011. p. 118: Abstract 528.Google Scholar
  23. 23.
    Matzdorff A, Arnold G. Treatment of chronic immune thrombocytopenic purpura: the patients’ perspective. Eur J Haematol. 2007;78:381–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549–54.PubMedCrossRefGoogle Scholar
  25. 25.
    Bussel JB, Rodeghiero F, Lyons RM, Firstenberg B, Joseph J, Kessler CM, et al. Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: report of 9 cases. Blood; 2011. p. 118: Abstract 3281.Google Scholar
  26. 26.
    Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, Yazdanbakhsh K. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112:1325–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116:4639–45.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Shinya Katsutani
    • 1
  • Yoshiaki Tomiyama
    • 2
  • Akiro Kimura
    • 3
  • Yoshitaka Miyakawa
    • 4
  • Shinichiro Okamoto
    • 4
  • Yasushi Okoshi
    • 5
  • Haruhiko Ninomiya
    • 5
  • Hiroshi Kosugi
    • 6
  • Kazuyoshi Ishii
    • 7
  • Yasuo Ikeda
    • 8
  • Toshihiro Hattori
    • 9
  • Koichi Katsura
    • 9
  • Yuzuru Kanakura
    • 10
  1. 1.Hiroshima UniversityHiroshimaJapan
  2. 2.Osaka University HospitalSuitaJapan
  3. 3.Kure-kyosai HospitalKureJapan
  4. 4.Keio UniversityTokyoJapan
  5. 5.University of TsukubaTsukubaJapan
  6. 6.Ogaki Municipal HospitalOgakiJapan
  7. 7.Kishiwada City HospitalKishiwadaJapan
  8. 8.Waseda University Faculty of Science and EngineeringShinjukuJapan
  9. 9.GlaxoSmithKlineShibuyaJapan
  10. 10.Osaka University Graduate School of MedicineSuitaJapan

Personalised recommendations